Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Inhibikase Therapeutics (IKT): which funds own it

Health Care →(by SIC code, unreviewed)Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow IKT for free
Share

Sections with a free account

6 concentrated managers hold it (+1 vs last quarter) with a median weight of 0.7%.

Who owns Inhibikase Therapeutics?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): RA Capital Management, 9.9% (13G/A filed Jul 31, 2026), Commodore Capital, 9.9% (13G/A filed May 15, 2026), ADAR1 Capital Management, 9.9% (13G/A filed May 15, 2026), Fairmount Funds Management, 9.9% (13G/A filed Feb 17, 2026) and Sands Capital Life Sciences Pulse Fund II, 9.3% (13G/A filed Aug 13, 2026). Sands Frank M. is listed on Form 4 filings as an owner of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were Sands Capital Alternatives (9.9% of the shares), Soleus Capital Management (8.2%) and Trails Edge Capital Partners (6.9%).

Which institutions hold the most Inhibikase Therapeutics shares?

Per Form 13F filings as of Jun 30, 2026, as a share of all shares outstanding:

  1. 1. Sands Capital Alternatives: 9.9%
  2. 2. Soleus Capital Management: 8.2%
  3. 3. Trails Edge Capital Partners: 6.9%
  4. 4. Fairmount Funds Management: 6.5%
  5. 5. BlackRock: 5.9%
  6. 6. ADAR1 Capital Management: 5.6%
  7. 7. Blackstone: 4.5%
  8. 8. Siren, L.L.C: 4.4%
  9. 9. Commodore Capital: 4.1%
  10. 10. Vanguard Capital Management: 3.7%

How much of Inhibikase Therapeutics do institutions own?

The 105 institutions that file 13F reported 89.3% of the shares as of Jun 30, 2026.

Sources:13G/A by RA Capital Management (Jul 31, 2026) ↗13G/A by Commodore Capital (May 15, 2026) ↗13G/A by ADAR1 Capital Management (May 15, 2026) ↗13G/A by Fairmount Funds Management (Feb 17, 2026) ↗13G/A by Sands Capital Life Sciences Pulse Fund II (Aug 13, 2026) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (May 1, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Inhibikase Therapeutics revenue

Inhibikase Therapeutics reported annual revenue of $260,501 for fiscal year 2023 (year ended December 31, 2023), according to its Form 10-K filed with the SEC (XBRL data).

Concentrated managers
6
All 13F: 105
Consensus
32/100
across 6 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$2.03
+20.8% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (5 → 6): 1 opened · 0 exited = +1

Net flow in the quarter: +$41K (+20 K shares) · bought $41K and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

The set of concentrated managers changed between quarters: with the set as it was then, 6 held it last quarter (the chart point); with today's set, 5 (the base for the change).

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of IKT (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 89.3% of the shares · top 10: 59.7% · in index firms: 17.0% of the institutional total

Share of the stock held by 13F filers

Q2 2026: 89.3%

141.6%2.4%
Q2 2023Q2 2026

Shares reported by the 105 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (May 1, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Fundamentals

12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.

Profitability
Operating margin
—
Net margin
—
ROE
-39.5%
Growth
Revenue (TTM)
—
Revenue growth
—
Net income (TTM)
$-60.6M
Balance sheet
Net debt / EBITDA
—
Free cash flow (TTM)
$-42.6M
Quality vs sector
—

This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Shares outstanding: buybacks and dilution

Diluted shares by fiscal year (split-adjusted)

2025: 98.3 M

98.3 M0
20212025

There is a jump that may be an undetected split: we do not show the changes.

Buybacks (FY 2025)
no data
Share issuance
$108M
Stock-based compensation
$15.3M
Dividends paid
no data

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
no datanot calculated with negative net income
Debt due within 12 months
no data

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
0
Amount (6 m)
$0
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Aug 26, 2026Mediumfiling ↗

    Change of auditor (Item 4.01)

  • Oct 20, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors»

  • Jul 29, 2026Routinefiling ↗

    Unregistered sale of equity securities (Item 3.02)

  • Jun 29, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow IKT for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow IKT